Estrogens, Estrogen Receptors and Tumor Microenvironment in Ovarian Cancer.
estrogen receptors
estrogens
ovarian cancer
proliferation
tumor microenvironment
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
28 Sep 2023
28 Sep 2023
Historique:
received:
28
08
2023
revised:
20
09
2023
accepted:
26
09
2023
medline:
23
10
2023
pubmed:
14
10
2023
entrez:
14
10
2023
Statut:
epublish
Résumé
Ovarian cancer is one of the most common cancers in women and the most concerning issues in gynecological oncology in recent years. It is postulated that many factors may contribute to the development of ovarian cancer, including hormonal imbalance. Estrogens are a group of hormones that have an important role both in physiological and pathological processes. In ovarian cancer, they may regulate proliferation, invasiveness and epithelial to mesenchymal transition. Estrogen signaling also takes part in the regulation of the biology of the tumor microenvironment. This review summarizes the information connected with estrogen receptors, estrogens and their association with a tumor microenvironment. Moreover, this review also includes information about the changes in estrogen receptor expression upon exposition to various environmental chemicals.
Identifiants
pubmed: 37834120
pii: ijms241914673
doi: 10.3390/ijms241914673
pmc: PMC10572993
pii:
doi:
Substances chimiques
Receptors, Estrogen
0
Estrogens
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical University of Lodz
ID : 503/0-078-03/503-01-001
Références
Cell Death Dis. 2022 Aug 4;13(8):675
pubmed: 35927239
J Ovarian Res. 2013 Jul 13;6(1):51
pubmed: 23849542
Cell Death Dis. 2020 Apr 20;11(4):249
pubmed: 32312959
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Gynecol Oncol. 2021 Feb;160(2):530-538
pubmed: 33317907
Tumour Biol. 2017 Jul;39(7):1010428317712592
pubmed: 28718374
Endocr Relat Cancer. 2013 Aug 23;20(5):R257-67
pubmed: 23878074
Cancers (Basel). 2020 Jun 22;12(6):
pubmed: 32580290
Nat Rev Endocrinol. 2017 Apr;13(4):220-231
pubmed: 27716751
Cancers (Basel). 2020 Sep 15;12(9):
pubmed: 32942545
Cancer Biol Ther. 2019;20(7):956-966
pubmed: 31062668
J Endocrinol. 2007 Jun;193(3):421-33
pubmed: 17535880
Steroids. 2013 Jun;78(6):530-7
pubmed: 23402742
Pharmacol Ther. 2012 Jul;135(1):54-70
pubmed: 22484805
Front Endocrinol (Lausanne). 2022 Aug 18;13:839005
pubmed: 36060947
Toxicol In Vitro. 2019 Apr;56:184-193
pubmed: 30682495
Cell Prolif. 2020 Feb;53(2):e12739
pubmed: 31820522
Toxicol Appl Pharmacol. 2013 Nov 1;272(3):637-46
pubmed: 23933164
Front Oncol. 2021 Sep 08;11:682917
pubmed: 34568014
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Int J Mol Sci. 2022 Feb 17;23(4):
pubmed: 35216340
Cell Biochem Funct. 2015 Dec;33(8):552-9
pubmed: 26526233
Stroke. 2022 Oct;53(10):3107-3115
pubmed: 35735009
Int J Mol Sci. 2018 Feb 19;19(2):
pubmed: 29463044
Clin Cancer Res. 2017 Jan 15;23(2):587-599
pubmed: 27401249
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
Br J Cancer. 2020 Mar;122(6):778-788
pubmed: 31932754
Breast Cancer Res Treat. 2022 Jan;191(2):269-275
pubmed: 34731351
Oncotarget. 2016 Jul 12;7(28):43076-43087
pubmed: 27172798
PLoS One. 2012;7(9):e44787
pubmed: 22970307
Cancer Res. 2013 Aug 15;73(16):5016-28
pubmed: 23824740
Mol Med Rep. 2020 Sep;22(3):2318-2328
pubmed: 32705198
Front Endocrinol (Lausanne). 2021 Feb 19;12:564002
pubmed: 33679613
Nat Commun. 2018 Apr 27;9(1):1685
pubmed: 29703902
Cancers (Basel). 2022 May 06;14(9):
pubmed: 35565440
Toxicol Lett. 2023 Sep 1;386:9-19
pubmed: 37683805
Cancer Discov. 2012 Dec;2(12):1100-8
pubmed: 23171795
Int Immunopharmacol. 2016 Nov;40:184-195
pubmed: 27608303
Immunol Invest. 2023 Nov;52(5):616-634
pubmed: 37310730
Cancer Biol Ther. 2017 Sep 2;18(9):730-739
pubmed: 27689466
J Ovarian Res. 2012 Nov 19;5(1):35
pubmed: 23163984
Int J Gynecol Pathol. 2013 Nov;32(6):576-84
pubmed: 24071874
Pharmacol Ther. 2021 May;221:107753
pubmed: 33259885
Breast Cancer Res Treat. 2013 Nov;142(1):211-23
pubmed: 24122391
Mol Cell Biochem. 2013 Jun;378(1-2):1-7
pubmed: 23580092
Food Chem Toxicol. 2013 Sep;59:373-9
pubmed: 23810794
BMC Cancer. 2017 May 8;17(1):319
pubmed: 28482871
Front Pharmacol. 2022 Jan 24;13:820969
pubmed: 35140617
Clin Colorectal Cancer. 2018 Jun;17(2):e281-e288
pubmed: 29398422
Environ Sci Pollut Res Int. 2021 Jul;28(27):36060-36068
pubmed: 33683587
J Clin Invest. 2010 Apr;120(4):963-72
pubmed: 20364094
Trends Endocrinol Metab. 2009 Dec;20(10):477-82
pubmed: 19783454
Front Biosci (Landmark Ed). 2010 Jan 01;15(1):166-79
pubmed: 20036813
J Inflamm (Lond). 2022 Jul 16;19(1):11
pubmed: 35842650
Endocr Rev. 2023 Jan 12;44(1):117-141
pubmed: 35709009
Clin Transl Oncol. 2023 Jun;25(6):1606-1616
pubmed: 36593384
Gynecol Oncol. 2009 Sep;114(3):465-71
pubmed: 19501895
Gynecol Oncol. 2004 Jul;94(1):25-32
pubmed: 15262115
J Immunol. 2009 Apr 15;182(8):4499-506
pubmed: 19342621
Int J Mol Sci. 2019 Jan 12;20(2):
pubmed: 30642093
Int J Oncol. 2020 Feb;56(2):407-416
pubmed: 31894326
J Ovarian Res. 2012 Mar 18;5:9
pubmed: 22424333
Res Pharm Sci. 2018 Dec;13(6):493-499
pubmed: 30607147
J Gene Med. 2022 Oct;24(10):e3446
pubmed: 36027869
Cent Eur J Immunol. 2017;42(4):383-389
pubmed: 29472817
Cancer Manag Res. 2021 Sep 21;13:7355-7363
pubmed: 34584460
Int J Mol Sci. 2021 Jan 05;22(1):
pubmed: 33466512
Mol Endocrinol. 2008 Sep;22(9):2085-98
pubmed: 18550773
Lancet. 2015 May 9;385(9980):1835-42
pubmed: 25684585
Front Endocrinol (Lausanne). 2014 Nov 12;5:192
pubmed: 25429284
Cancer Res. 1998 Dec 1;58(23):5367-73
pubmed: 9850067
Inflammation. 2019 Oct;42(5):1517-1529
pubmed: 31049770
Nat Rev Cancer. 2011 Jul 22;11(8):597-608
pubmed: 21779010
J Ovarian Res. 2021 Jun 2;14(1):74
pubmed: 34078414
Oncogene. 2021 Jul;40(26):4503-4519
pubmed: 34117361
Front Cell Dev Biol. 2020 Dec 21;8:591239
pubmed: 33425895
J Clin Oncol. 2015 Dec 10;33(35):4138-44
pubmed: 26417001
Cells. 2020 May 22;9(5):
pubmed: 32456078
FASEB J. 2022 Nov;36(11):e22597
pubmed: 36197688
Prog Brain Res. 2010;181:209-32
pubmed: 20478440
Front Endocrinol (Lausanne). 2022 Mar 01;13:827032
pubmed: 35299973
Exp Mol Pathol. 2016 Feb;100(1):17-25
pubmed: 26607602
Int J Oncol. 2021 May;58(5):
pubmed: 33649784
Pathol Res Pract. 2018 Sep;214(9):1345-1351
pubmed: 30049511
Immunity. 2013 Sep 19;39(3):611-21
pubmed: 24012420
Cancer Lett. 2011 Apr 1;303(1):47-55
pubmed: 21310528
Toxicol In Vitro. 2017 Dec;45(Pt 1):54-59
pubmed: 28811233
Science. 2005 Mar 11;307(5715):1625-30
pubmed: 15705806
Cell Death Dis. 2013 Oct 17;4:e869
pubmed: 24136233
Open Med (Wars). 2023 Jun 09;18(1):20230729
pubmed: 37333452
Oncol Rep. 2017 Jul;38(1):522-528
pubmed: 28586039
Cancer Cell Int. 2018 May 01;18:65
pubmed: 29743815
FEBS J. 2020 Dec;287(23):5218-5235
pubmed: 32239647